Resistance of Hematological Malignancies to CAR T Cell Therapy
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 30 September 2024 | Viewed by 1090
Special Issue Editor
Interests: immunotherapy; NHL; ALL; apoptosis; signal transduction; adoptive cell therapy; resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Remarkable clinical responses have been observed in patients with hematological malignancies such as non-Hodgkin’s lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma (MM) using modern immune-based approaches such as CD19CAR redirected adoptive T cell therapy (CAR T cell). Chimeric antigen receptors (CARs) bestow autologous T cells with antigen-specific recognition of tumor cells, activation, and proliferation independent of the major histocompatibility complex. Engineered T cell therapy (CAR and T cell receptor (TCR) engineered T lymphocytes) has shown increasing promise in clinical investigations at multiple institutions across the nation and abroad. Considerable effort has been dedicated to effector cell production (e.g., high transduction rates) and the intensity of the conditioning regimen; much less attention has been paid to the tumor and its microenvironment. It is well-established that cytotoxic T cells kill tumor targets via non-receptor (perforin/granzyme) and receptor-mediated (TNFa/TNF-R1, TNF-R2, TRAIL/TRAIL receptors (DR4, DR5, DcR1, DcR2), and Fas (CD95)/FasL (CD95L)) apoptotic signal transduction pathways. In turn, tumors may have inherent/preexisting resistance to apoptotic death signals through a variety of mechanisms. Alternatively, tumors may develop resistance to engineered T cells upon successful initial therapy, resulting in tumor recurrence or relapse. This is due to altered dynamics of the expression profile of pro- and anti-apoptotic proteins (due to deregulation/constitutive hyper-activation of various signal transduction pathways such as NF-kB, JAK/STAT, MAPK, AKT/ PKB, etc.) favoring an anti-apoptotic tumor milieu.
Although very effective, innovative strategies are needed to improve CD19CAR T cell therapy, both in responding patients and in instances where tumors may have varying degrees of preexisting or acquired resistance to T cell-delivered apoptotic death signals. Understanding these mechanisms and obtaining strategies to render tumor cells more receptive to T cell killing could result in better response rates, reducing the intensity of the conditioning regimen or even the number of infused CAR T cells needed. This Special Issue focuses on the inherent or acquired resistance mechanisms of tumor cells which render them unresponsive to tumor-specific and highly effective CAR T cells and the design of novel strategies to render tumors sensitive to apoptotic death signals delivered by CAR T cells, thus creating a proapoptotic tumor microenvironment (immune-sensitization).
Dr. Ali R. Jazirehi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NHL
- ALL
- CAR T cell
- immunotherapy
- resistance
- apoptosis
